OBJECTIVES Suboptimal blood pressure (BP) control is commonly observed in patients receiving antihypertensive agents, but it remains unknown the relationship between uncontrolled BP and early impairment of left atria (LA) function.
Parameters
Controls HT gp HTgp1 HTgp2
HTgp1 vs.
HTgp2
Systolic CONCLUSIONS Hypertensive patients are associated with early impairment of LA myocardial function detected by TDI and free strain speckle tracking. Furthermore, early impairment of LA function could be attribute to suboptimal BP control as these patients are associated with reduced V Ea and S Ea , therefore, more intensive therapy should be considered.
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Serum Cystatin C as a Potential Predictor for the Progression of Prehypertension-to-hypertension OBJECTIVES Cystatin C (CysC) is considered to be a risk factor of cardiovascular diseases. However, the association between CysC and the progression of prehypertension-to-hypertension is not evaluated before.
METHODS A total of 463 consecutive patients with prehypertension were enrolled. Serum CysC levels at baseline were measured via an immunoturbidimetric technique. Then, all subjects underwent a median three-year follow-up. The primary endpoint was the progression of prehypertension-to-hypertension diagnosed by upper-arm blood pressure monitor. A proportional hazard regression analysis was implemented to model the interval-censored progression-free survival time data. Receiver operating characteristic curves (ROC) and multivariate logistic regression analysis were used to evaluate the predictive value of serum CysC.
RESULTS At last, a total of 124 prehypertensive patients progressed to hypertension, with a progression rate of 26.78%. Serum CysC levels were positively associated with the progression rate (hazard ratio: 1.82, 95% CI: 1.32-1.93). Multivariate logistic regression analysis considered that increased baseline serum CysC level [OR:1.385 (1.052, 2.836), p<0.001] was an independent predictor for the progression of prehypertension-to-hypertension. ROC analysis showed that the AUC of serum CysC for predicting the progression of prehypertension-tohypertension was 0.824 (95%CI 0.734-0.912), with an optimum cut-off of 1.18mg/dl.
CONCLUSIONS Serum CysC might serve as a potential predictor for the progression of prehypertension-to-hypertension. OBJECTIVES Last year we reported that lifestyle modification in patients with stage 1 hypertension could achieve goal of blood pressure. Additional perindopril therapy could achieve lower blood pressure with lower sensitivity C-reactive protein (hsCRP) and macrophage inhibitory factor (MIF) serum levels. But the difference was slight which might be associated with the short period of follow-up (8 weeks). In order to further define the anti-inflammatory effect of hypotenser treatment on stage 1 hypertension patients, we extended the follow-up period to 1 year and monitored the above indexes.
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METHODS 86 patients were enrolled into the study after signing informed consent and they were divided into lifestyle modification group (average age 54.1AE7.2yrs) and perindopril therapy group (average age 56.1AE6.7yrs) by matched pair design. Perindopril therapy was added in the latter group while both groups received lifestyle modification. Peripheral serum was collected at the time of enrollment, week 4, week 8, week 12, week 24, week 36 and week 48. ELISA was applied to determine the serum level of hsCRP and MIF. Patients' financial expense on medication was recorded. Data was finally analyzed by SPSS 19.0.
RESULTS
In the last year's submission we showed that additional perindopril therapy led to better blood pressure control, with lower hsCRP and MIF but the difference was slight at week 4 and 8. After 1 year's follow-up there were 8 lost cases (9.3%, 5 cases in lifestyle modification group v.s. 3 cases in perindopril therapy group) (P>0.05).
There was still no significant difference of blood pressure between two groups at week 12 and week 24. At week 36 and week 48 perindopril therapy group showed lower systolic blood pressure ( CONCLUSIONS Age, gender, SBP, anemia, LVMI. etc are risk factors for LAE. It is urgent for us to detect and intervene LAE early, in order to reduce the reverse events.
GW26-e0006
Associations of plasma homocysteine and high normal blood pressure with arterial stiffness in Chinese healthy population: result from the China stroke primary prevention study (CSPPT)
Geng Qian, 1 Yundai Chen, 1 Yong Huo 2 1 Chinese People's Liberation Army General Hospital; 2 Peking University First Hospital OBJECTIVES Pulse wave velocity (PWV) as direct indication of arterial stiffness is a critical predictor of cardiovascular events, there is a lack of research on the correlation between plasma homocysteine (Hcy) and arterial stiffness in large community-based sample of the Chinese population.
METHODS Plasma homocysteine and other cardiovascular disease risk factor variables were measured in 2148 community healthy people enrolled in the CSPPT Study. Large-artery stiffness was assessed in terms of brachial-ankle PWV (baPWV).
RESULTS
The mean age of the population was (62.5 AE 7.5) years, more females (63.8%) and their average Hcy level was (14.17 AE 4.70) mmol/L while average level of baPWV was (1586 AE 379) cm/s. BaPWV was positively correlated with Hcy in entire group after adjustment for age, gender and other CAD risk factors (b Hcy ¼5.32, p<0.001). There was a significant interaction effect of the blood pressure (BP) on arterial stiffness, the impact of Hcy on baPWV of subjects with the high normal BP was more significant than that of individuals with the optimal normal pressure (b Hcy : 2.55 vs. 9.88, p¼0.004). We chose optimal BP group as a reference, in whole population PWV showed a significantly positive correlation with different level of BP: Normal BP (b BP ¼101, p<0.001), high normal BP (b BP ¼193, p<0.001), Grade 1 hypertension (b BP ¼413, p<0.001). Regression analysis of PWV between high normal BP and homocysteine revealed a significant interaction between BP level and Hcy on baPWV.
CONCLUSIONS Plasma Hcy was an independent correlate of arterial stiffness in the Chinese community population. High normal blood pressure may worsen the impact of Hcy on arterial stiffness, and is a major link between Hcy and aortic arterial stiffness.
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Characteristics of Traditional Chinese Medicine Constitutions and the relationship with hypertension in adult Chinese resident: a cross-sectional study METHODS 46 Patients with PA was recruited between 2008 to 2012 from the people' hospital of Xinjiang Uygur Autonomous Region. The surgical adrenal specimens and adjacent adrenal tissue were collected and stored in liquid nitrogen immediately after excision and maintained at -80C. Genomic DNA was prepared from adrenal tissues and peripheral blood. and all exons including the 5'-and 3'-untranslated regions (UTRs) (w1kb) of KCNJ5 gene were PCR amplified.PCR products were sequenced using an optimized direct sequencing analysis protocol.Serum ALD, Serum sodium, potassium, and creatinine levels were measured. The LV dimension was measured by Doppler echocardiogram.
RESULTS Three missense mutations were found in tissues of 46 patients with APA:C.451G>C/A(p.G151R)(5/46), c.503T>G(p.L168R) (4/46), C.830T>A(p.S209T)(12/46) S209T. There is no significant difference between the wild type group and the mutation group on gender, age, hypertension duration, systolic blood pressure, diastolic blood pressure, serum Kþ, tumor diameter, seated ALD, seated RAR, ARR, serum lipid, IVS, LVM, LVEDD, LVESD and LVM1 (p＞0.05). uric Kþ and EF showed significant difference between the wild type and the mutation group. Comparison of the baseline date among G151R, L168R and S209T, The patients with G151R mutation had higher SBP and DBP than L168R and S209T (p<0.05) and had the lowest serum Kþ and the highest uric Kþ than other groups.
CONCLUSIONS The mutations of the KCNJ5 gene have related to clinical phenotype in patients with aldosterone-producing adenoma.
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The relationship between the KCNJ5 gene polymorphisms and lipid metabolism in patients with primary aldosteronism Niluofeier aierken, Nanfang Li, Dilinigeer Tuerxun, Jing Hong, Xinyu Du The Center of Hypertension of the People's Hospital of Xinjiang Uygur Autonomous Region, Hypertension Institute of Xinjiang
